Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
119.73 K
Value Traded
2.99 K
Short % Float
-
Days to Cover
3.1
+67.6%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ADAPY Catalyst Timeline
Dated clinical, regulatory and corporate events for Adaptimmune Therapeutics PLC
Past FDA Catalysts and PDUFA Decisions
How ADAPY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 81%
Micro Cap(rank 587 of 724)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| gavo-cel Cell TherapiesNCT03907852 | Mesothelioma | Phase 1/2 | ACTIVE NOT_RECRUITING | 57 | Nov 2, 2028 | ||||||
| TC-110 T Cells Small MoleculesCompletedNCT04323657 | Non Hodgkin Lymphoma | Phase 1/2 | COMPLETED | 6 | Feb 24, 2023 | ||||||
| ADP-A2AFP Gene TherapiesCompletedNCT03132792 | Hepatocellular Cancer | Phase 1 | COMPLETED | 39 | Nov 19, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ADAPY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wood GavinOfficer (Chief Financial Officer) | Sell | -96,000 | $0.01 | 09/02/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in ADAPY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ADAPY for Q2 2026. | ||||
Ownership Trends
ADAPY Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
1.2M
Shares Sold Short
+0.0% vs prior count
3.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
390.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ADAPY ranks across every disease it competes in
Competitive Position is a premium feature
See how ADAPY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialADAPY News
About Adaptimmune Therapeutics PLC
BIOPHARMAWATCH ELITE
Trade the next ADAPY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime